Phoenix Biotech Acquisition Corp.
Phoenix Biotech Acquisition Corp. (PBAX) Revenue
Annual & quarterly revenue history · segment & region breakdown
PBAX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsPhoenix Biotech Acquisition Corp. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2021 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Phoenix Biotech Acquisition Corp. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Phoenix Biotech Acquisition Corp. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Phoenix Biotech Acquisition Corp.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
PBAX revenue · 4 questionsPBAX's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Phoenix Biotech Acquisition Corp. SEC filings · GAAP · Phoenix Biotech Acquisition Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026